返回Google圖書搜尋

Intravenous Naloxone Utilization Among Hospitalized Cancer Patients On Opioids At A Tertiary Cancer Center

出版	Morressier, 2017
URL	http://books.google.com.hk/books?id=5jd-zgEACAAJ&hl=&source=gbs_api

註釋Introduction: Intravenous naloxone is used to reverse respiratory depression and progressive sedation resulting from opioid overdose. Monitoring hospitalu2019s use of naloxone is an important metric to examine trends related to opioid safety. Objectives: To quantitate naloxone use among hospitalized adult (>18 years) cancer patients at a tertiary cancer center. Methods: Inpatient admissions between January 01, 2017 and December 31, 2017 were retrospectively reviewed. Data collected included admission source (emergency center (EC), outpatient operation theater (OT), or others) and the administration of opioids and naloxone.Results: We identified 15,861 unique cancer patients (solid tumors 77% and hematological malignancies 23%) that accounted for 27,876 admissions, resulting in 225,997 inpatient-days. Total inpatient-days with opioid use was 150,775 (67%) and inpatient-days with both opioids and naloxone use was 549 (445 unique patients). Incidence rate of naloxone administration per 1,000 inpatient opioid days was 3.64%. Patients admitted via EC had higher frequency of naloxone administration (1.75%, 234/13,388) as compared to OR (1.41%, 95/6,726) and others (1.30%, 101/7,762)( P